Medix Biochemica

Building a global leader in critical components for diagnostic tests

Medix Biochemica
CEO

Ismo Råman

Board of Directors

Ann-Christine Sundell (Chairman)
Teemu Alahuhta (Vice Chairman)
Pekka Mattila
Kerttu Tuomas
Timo Ahopelto
Juhani Laakso

Year of DevCo investment

2018

Revenue (2018)

€23m

Employees (2018)

120

Share of exports (% of revenue)

90%+

DevCo is a great partner for Minerva in several key ways; in addition to being a local long-term partner with significant financial capacity and a hands-on business development approach, DevCo was able to complete our partnership in a swift and flexible manner.

Caj Haglund – Chairman of the Board of Minerva Foundation

What is Medix Biochemica?

Medix Biochemica is a global leader in development and manufacturing of monoclonal antibodies and recombinant antigens for the in vitro diagnostics industry. In addition, it offers diagnostic tests specifically designed for the women’s health sector. The company was founded in 1985 and it currently employs about 120 people in its locations in Europe, the US and China. Medix Biochemica has a strict focus on quality - it has an ISO 13485 certificate and its operations are also FDA QSR compliant.

DevCo team has really stood behind its words in terms of active support for Medix both on an operational and board level. And it has been fun to work with them!

Ann-Christine Sundell – Chairman of the Board of Medix Biochemica

Why did we invest in Medix Biochemica?

DevCo has, for a long time, regarded in vitro diagnostics (IVD) as a fundamentally attractive growth market which is supported by strong global trends such as aging of population. Furthermore, tests continue to improve as a result of continuous research. Following a careful review of the IVD sector and several companies operating in it, Medix Biochemica was seen as a particularly attractive platform company for DevCo, due to its attractive value chain position as a developer and provider of critical components for diagnostic tests, excellent reputation among customers in all regions, and high quality of its in vitro manufacturing operations. In addition to significant organic growth potential in the long term, DevCo sees opportunities for Medix Biochemica to drive consolidation in its markets as part of its strategy to become the #1 choice in IVD.


Impact on society

As a global pioneer in monoclonal antibodies for the IVD industry, Medix Biochemica has to date provided critical components for more than 10 billion laboratory tests in all major regions.

DevCo is a great partner for Minerva in several key ways; in addition to being a local long-term partner with significant financial capacity and a hands-on business development approach, DevCo was able to complete our partnership in a swift and flexible manner.

Caj Haglund – Chairman of the Board of Minerva Foundation

Get in touch

We provide companies with full-time hands-on resources, tailored ownership solutions and significant capital for growth

Contact us